Last reviewed · How we verify

Pegylated rhG-CSF: 100µg/kg

Jiangsu HengRui Medicine Co., Ltd. · Phase 3 active Small molecule

Pegylated rhG-CSF: 100µg/kg is a Pegylated cytokine; G-CSF analog Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 3 development for Chemotherapy-induced neutropenia (CIN), Severe congenital neutropenia, Idiopathic or cyclic neutropenia.

Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.

Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts. Used for Chemotherapy-induced neutropenia (CIN), Severe congenital neutropenia, Idiopathic or cyclic neutropenia.

At a glance

Generic namePegylated rhG-CSF: 100µg/kg
SponsorJiangsu HengRui Medicine Co., Ltd.
Drug classPegylated cytokine; G-CSF analog
TargetG-CSF receptor (GCSFR)
ModalitySmall molecule
Therapeutic areaOncology; Hematology
PhasePhase 3

Mechanism of action

G-CSF is a cytokine that binds to G-CSF receptors on hematopoietic progenitor cells, promoting their maturation into functional neutrophils. Pegylation extends the drug's half-life by reducing renal clearance and increasing circulation time, allowing for less frequent dosing compared to non-pegylated G-CSF. This results in sustained elevation of neutrophil counts, reducing infection risk in patients with chemotherapy-induced neutropenia or other neutropenic conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pegylated rhG-CSF: 100µg/kg

What is Pegylated rhG-CSF: 100µg/kg?

Pegylated rhG-CSF: 100µg/kg is a Pegylated cytokine; G-CSF analog drug developed by Jiangsu HengRui Medicine Co., Ltd., indicated for Chemotherapy-induced neutropenia (CIN), Severe congenital neutropenia, Idiopathic or cyclic neutropenia.

How does Pegylated rhG-CSF: 100µg/kg work?

Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.

What is Pegylated rhG-CSF: 100µg/kg used for?

Pegylated rhG-CSF: 100µg/kg is indicated for Chemotherapy-induced neutropenia (CIN), Severe congenital neutropenia, Idiopathic or cyclic neutropenia.

Who makes Pegylated rhG-CSF: 100µg/kg?

Pegylated rhG-CSF: 100µg/kg is developed by Jiangsu HengRui Medicine Co., Ltd. (see full Jiangsu HengRui Medicine Co., Ltd. pipeline at /company/jiangsu-hengrui-medicine-co-ltd).

What drug class is Pegylated rhG-CSF: 100µg/kg in?

Pegylated rhG-CSF: 100µg/kg belongs to the Pegylated cytokine; G-CSF analog class. See all Pegylated cytokine; G-CSF analog drugs at /class/pegylated-cytokine-g-csf-analog.

What development phase is Pegylated rhG-CSF: 100µg/kg in?

Pegylated rhG-CSF: 100µg/kg is in Phase 3.

What are the side effects of Pegylated rhG-CSF: 100µg/kg?

Common side effects of Pegylated rhG-CSF: 100µg/kg include Bone pain, Headache, Fatigue, Injection site reactions, Splenomegaly, Elevated uric acid.

What does Pegylated rhG-CSF: 100µg/kg target?

Pegylated rhG-CSF: 100µg/kg targets G-CSF receptor (GCSFR) and is a Pegylated cytokine; G-CSF analog.

Related